Trending Now
Category: Press Releases
A universidade de inteligência artificial de Abu Dhabi cria departamentos dedicados à robótica e às ciências informáticas para responder à crescente procura mundial
August 4, 2023
ABU DHABI, Emirados Árabes Unidos, Aug. 04, 2023 (GLOBE NEWSWIRE) — A Mohamed bin Zayed University of Artificial Intelligence (MBZUAI)
جامعة محمد بن زايد للذكاء الاصطناعي تطلق برامج في علم الروبوتات وعلوم الحاسوب
August 4, 2023
تلبية للطلب المتزايد على هذه التخصصات على مستوى العالم أبوظبي، الإمارات العربية المتحدة، 3 أغسطس 2023: أطلقت جامعة محمد بن
Abu Dhabi’s artificial intelligence university establishes dedicated robotics and computer science departments to meet surging global demand
August 3, 2023
ABU DHABI, United Arab Emirates, Aug. 03, 2023 (GLOBE NEWSWIRE) — Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) has
Zenas BioPharma annonce la publication d’une étude de phase 2 sur l’obéxélimab, un traitement expérimental pour la maladie liée aux IgG4 (ML-IgG4), dans The Lancet Rheumatology
August 3, 2023
L’étude a montré que l’obéxélimab produisait une amélioration clinique rapide, forte et soutenue, y compris une rémission clinique complète, chez
Zenas BioPharma Publica Fase 2 do Estudo Clínico do Obexelimabe, um Tratamento Investigativo da Doença Relacionada à IgG4 (IgG4-RD), no The Lancet Rheumatology
August 3, 2023
Estudo revelou que o obexelimabe produziu melhora clínica rápida, forte e sustentada, incluindo remissão clínica completa, na maioria dos pacientes
Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology
August 1, 2023
Study found obexelimab produced rapid, strong, and sustained clinical improvement, including complete clinical remission, in most patients with active IgG4-RD
